

Supplementary Information

for

Solvent Dependent Hindered Rotation versus Epimerization in Axially Chiral Thiohydantoin Derivatives: An Experimental and a Computational Study

Sule Erol Gunal^a, Ipek Azizoglu^a, Oya Arica^a, Zeynep Pinar Haslak^a, Viktorya Aviyente^{a*},

Ilknur Dogan^{a*}

^a Department of Chemistry, Bogaziçi University, Bebek, Istanbul, Turkey

Table of Contents

Potential energy surfaces for the SM to SP transformations of compound 1 around C _{aryl} -N _{sp2} bond through exo-cyclic oxygen site (TS_{ror-1}) and exo-cyclic sulfur site (TS_{ror-2})	S2
Free energy profile for the epimerization process of 5-benzyl-3-(<i>o</i> -tolyl)-2-thiohydantoin in the presence of CD ₃ OD molecules.....	S3
Experimental and calculated epimerization barriers for the forward ΔG^\ddagger_f , and the reverse ΔG^\ddagger_r (ΔG^\ddagger , <i>kJ/mol</i>) reactions (M06-2X/6-311+G**) and the corresponding experimentally determined rate constants (<i>k</i> , <i>s</i> ⁻¹) for compounds 1-4 , in ethanol.....	S5
3D representations of the GS and TS structures of compounds 1-4 and corresponding α , β and θ values (calculated at M062X/6-311+G** level of theory).....	S6
HPLC chromatograms of compounds 1-4	S8-S25
Exchange of deuterium with hydrogen atom at C-5 of compound 1 in CD ₃ OD.....	S26
¹ H NMR and ¹³ C NMR spectra of compounds.....	S28-S38




Fig. S1 Potential energy surfaces for the *SM* to *SP* transformations of compound **1** around C_{aryl}-N_{sp2} bond through exo-cyclic oxygen site (*TS_{rot-1}*) and exo-cyclic sulfur site (*TS_{rot-2}*).

Geometrical features and energetics of the compounds in Figure S1:

For *SM* enantiomer of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (compound **1**) the minima was located on the potential energy surface at a dihedral angle of $\theta_{a-b-c-d} = 96.27^\circ$. The rotational transition state structure *TS_{rot-1}*, where the *o*-aryl substituent methyl rotates via the exo-cyclic oxygen has $\theta_{a-b-c-d} = -0.24^\circ$ and the two rings are flat and coplanar because of the electron delocalization. C_{aryl}-N_{sp2} bond elongates from 1.433 Å to 1.458 Å in going from ground state structure *SM* to transition state structure *TS_{rot-1}*. $\theta_{a-b-c-d}$ was calculated to be -174.24° in *TS_{rot-2}* structure, where the *o*-aryl substituent methyl rotates via the exo-cyclic sulfur atom and the two rings slightly deviate from planarity since larger S atom induces steric repulsion with the *o*-aryl methyl group. C_{aryl}-N_{sp2} bond elongates from 1.433 Å to 1.468 Å in going from ground state structure *SM* to transition state structure *TS_{rot-2}*. As a consequence, *TS_{rot-2}* has a higher rotational energy barrier than *TS_{rot-1}*. In the ground state of *SP*, the thermodynamically favored product, $\theta_{a-b-c-d} = -78.61^\circ$. Compared to *SM*, in *SP*, *o*-aryl methyl and benzyl group at *R* position do not face each other which is sterically a more favorable orientation.




Fig. S2 Free energy profile for the epimerization process of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (compound **1**) in the presence of CD₃OD molecules.

Geometrical features and energetics of the compounds in Figure S2:

For the starting ground state conformation of **RM** enantiomer of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (compound **1**) in the presence of two CD₃OD molecules, the minima was located on the potential energy surface at a dihedral angle of $\theta_{a-b-c-d} = 74.36^\circ$. The transition state structure (**TS-1**) for deprotonation of **RM** embodies an eight-membered cyclic structure involving triple proton transfer. CD₃OD₁ abstracts the proton at the stereocenter C5 with a bond length of 1.64 Å and transfers its deuterium which is attached to oxygen atom to CD₃OD₂ while another deuterium transfer occurs from CD₃OD₂ to carbonyl oxygen on 5-membered ring of compound **1** with a bond length of 1.63 Å, yielding the enolate intermediate. In **TS-1** structure $\theta_{a-b-c-d} = 76.66^\circ$. C_{aryl}-N_{sp2} bond shortens from 1.432 Å to 1.429 Å, C=O bond elongates from 1.210 Å to 1.253 Å and C5-C_{benzene} bond shortens from 1.546 Å to 1.516 Å in going from ground state structure **RM** to transition state structure **TS-1**. In the **Enol-intermediate**, $\theta_{a-b-c-d} = 79.43^\circ$, $d(\text{C}_{\text{aryl}}-\text{N}_{\text{sp}2}) = 1.431 \text{ \AA}$, $d(\text{C}=\text{O}) = 1.335 \text{ \AA}$ and $d(\text{C}5-\text{C}_{\text{benzene}}) = 1.492 \text{ \AA}$. In the deuteration step of C5 to yield the deuterated **SM** stereoisomer (**TS-2**, $\theta_{a-b-c-d} = 84.32^\circ$, upper path in Fig. S2), C5 abstracts the deuterium from CD₃OD₁, which approaches from *re*-face of the compound,







with a bond length of 1.65 Å while CD₃OD₁ picks a deuterium from CD₃OD₂ and CD₃OD₂ abstracts the deuterium from carbonyl oxygen on 5-membered ring of compound **1** with a bond length of 1.78 Å. In going from ground state structure *Enol-intermediate* to transition state structure *TS-2* to yield *SM* stereoisomer, C_{aryl}-N_{sp2} bond shortens from 1.431 Å to 1.429 Å, C=O bond shortens from 1.335 Å to 1.248 Å and C5-C_{benzene} bond elongates from 1.492 Å to 1.505 Å. For the ground state conformation of deuterated *SM* enantiomer in the presence of two CD₃OD molecules, the minima was located on the potential energy surface at a dihedral angle of $\theta_{a-b-c-d} = 85.33^\circ$. On the other hand, to yield the deuterated *RM* stereoisomer, deuteration (*TS-2*, $\theta_{a-b-c-d} = 76.09^\circ$, lower path in Fig. S2) occurs from the *si*-face of the compound, with shorter C5 \cdots ₁D—OCD₃ (1.64 Å) and O \cdots ₂D—OCD₃ (1.62 Å) bonds. In going from ground state structure of *Enol-intermediate* to transition state structure *TS-2* to yield *RM* stereoisomer, C_{aryl}-N_{sp2} bond shortens from 1.431 Å to 1.429 Å, C=O bond shortens from 1.335 Å to 1.253 Å and C5-C_{benzene} bond elongates from 1.492 Å to 1.511 Å. For the ground state conformation of deuterated *RM* enantiomer in the presence of two CD₃OD molecules, the minima was located on the potential energy surface at a dihedral angle of $\theta_{a-b-c-d} = 75.32^\circ$.

Table S1. Experimental and calculated (*) epimerization barriers for the forward ΔG^\ddagger_f and the reverse ΔG^\ddagger_r (ΔG^\ddagger , *kJ/mol*) reactions (M06-2X/6-311+G**) and the corresponding experimentally determined rate constants (*k*, *s⁻¹*) for compounds **1-4**, in ethanol.

Compound	T (°C)	Stereoisomer conversion	ΔG^\ddagger_f	ΔG^\ddagger_r	<i>k_f</i>	<i>k_r</i>
1	25	SM to RM	100.4±1.2 106.1*	99.3±1.2	1.59 x 10 ⁻⁵	2.41 x 10 ⁻⁵
	25	RM to SM	100.5±1.2 107.4*	100.5±1.2	1.51 x 10 ⁻⁵	1.49 x 10 ⁻⁵
2	40	RP to SP	100.0±3.2	101.9±3.2	1.36 x 10 ⁻⁴	6.43 x 10 ⁻⁵
	40	SP to RP	104.6±3.2	102.7±3.2	2.26 x 10 ⁻⁵	4.74 x 10 ⁻⁵
	40	RM to SM	105.7±3.2	104.3±3.2 105.4*	1.48 x 10 ⁻⁵	2.52 x 10 ⁻⁵
3	25	RP to SP	99.4±1.8	100.2±1.8	2.30 x 10 ⁻⁵	1.70 x 10 ⁻⁵
	25	SP to RP	102.0±1.8	101.1±1.8	8.25 x 10 ⁻⁶	1.18 x 10 ⁻⁶
	25	RM to SM	102.0±1.8	101.1±1.8	8.28 x 10 ⁻⁶	1.17 x 10 ⁻⁶
	25	SM to RM	100.5±1.8 99.3*	100.6±1.8	1.53 x 10 ⁻⁵	1.47 x 10 ⁻⁵
4	40	RP to SP	102.1±0.1	103.1±0.1	5.97 x 10 ⁻⁵	4.04 x 10 ⁻⁵
	40	SP to RP	103.2±0.1	102.1±0.1	3.98 x 10 ⁻⁵	6.02 x 10 ⁻⁵
	40	RM to SM	103.0±0.1	102.2±0.1 101.6*	4.27 x 10 ⁻⁵	5.73 x 10 ⁻⁵

Table S2. 3D representations of the GS and TS structures of compounds 1-4 and corresponding α , β and θ values (calculated at M062X/6-311+G** level of theory).

COMPOUND 1 R₁: -benzyl X: -CH₃			
	$\theta_{c-d-e-f}$ α β	96.3° 126.5° 120.7°	-0.2° 128.5° 129.9°
COMPOUND 1 R₁: -benzyl X: -CH₃			
	$\theta_{c-d-e-f}$ α β	-96.3° 126.5° 120.7°	0.2° 128.5° 129.9°
COMPOUND 2 R₁: -benzyl X: -Br			

	<i>RP</i>	<i>TS_{rot-1}</i>	<i>RM</i>
$\theta_{c-d-e-f}$	-82.1°	-4.5°	80.1°
α	126.3°	128.0°	126.3°
β	119.8°	128.8°	119.9°
COMPOUND 3 R₁: -isobutyl X: -CH₃			
	<i>RM</i>	<i>TS_{rot-1}</i>	<i>RP</i>
$\theta_{c-d-e-f}$	75.7°	-0.7°	-78.8°
α	126.2°	128.1°	126.2°
β	120.9°	129.5°	120.6°
COMPOUND 4 R₁: -isobutyl X: -Br			
	<i>SP</i>	<i>TS_{rot-1}</i>	<i>SM</i>
$\theta_{c-d-e-f}$	-82.1°	3.4°	82.9°
α	126.1°	127.8°	126.1°
β	119.9°	128.7°	119.8°




Fig. S3 HPLC chromatograms of 5-benzyl-3-(*o*-bromophenyl)-2-thiohydantoin (**2**) (ChiralPak IC as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RP**, (c-d) conversion of **RP** to **SP** with time in **ethanol** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S4 HPLC chromatograms of 5-benzyl-3-(*o*-bromophenyl)-2-thiohydantoin (**2**) (ChiralPak IC as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RM**, (c-d) conversion of **RM** to **SM** with time in **ethanol** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.






Fig. S5 The plot of $\ln\left(\frac{[RM]_o - [RM]_{eq}}{[RM] - [RM]_{eq}}\right)$, $\ln\left(\frac{[SP]_o - [SP]_{eq}}{[SP] - [SP]_{eq}}\right)$, $\ln\left(\frac{[RP]_o - [RP]_{eq}}{[RP] - [RP]_{eq}}\right)$, versus time at 313 K in ethanol for 5-benzyl-3-(*o*-bromophenyl)-2-thiohydantoin (**2**).




Fig. S6 HPLC chromatograms of 5-benzyl-3-(*o*-bromophenyl)-2-thiohydantoin (**2**) (ChiralPak IC as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RP**, (c-d) conversion of **RP** to **RM** with time in **toluene** at 383 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S7 The plot of $\ln\left(\frac{[RP]_0 - [RP]_{eq}}{[RP] - [RP]_{eq}}\right)$ versus time at 383 K in toluene for 5-benzyl-3-(*o*-bromophenyl)-2-thiohydantoin (**2**) .




Fig. S8 HPLC chromatograms of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (ChiralPak IB as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **SM**, (c-d) conversion of **SM** to **RM** with time in **ethanol** at 298 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S9 HPLC chromatograms of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (ChiralPak IB as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate: 0.8 ml/min, column temperature : 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RM**, (c-d) conversion of **RM** to **SM** with time in **ethanol** at 298 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S10 HPLC chromatograms of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (ChiralPak IB as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **SP**, (c-d) conversion of **SP** to **RP** with time in **ethanol** at 298 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S11 HPLC chromatograms of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (ChiralPak IB as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RP**, (c-d) conversion of **RP** to **SP** with time in **ethanol** at 298 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S12 The plot of $\ln\left(\frac{[SM]_o - [SM]_{eq}}{[SM] - [SM]_{eq}}\right)$, $\ln\left(\frac{[SP]_o - [SP]_{eq}}{[SP] - [SP]_{eq}}\right)$, $\ln\left(\frac{[RM]_o - [RM]_{eq}}{[RM] - [RM]_{eq}}\right)$, $\ln\left(\frac{[RP]_o - [RP]_{eq}}{[RP] - [RP]_{eq}}\right)$, versus time in **ethanol** at 298 K for 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**).




Fig. S13 HPLC chromatograms of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (ChiralPak IB as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RM**, (c-d) conversion of **RM** to **RP** with time in **toluene** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S14 The plot of $\ln\left(\frac{[RM]_0 - [RM]_{eq}}{[RM] - [RM]_{eq}}\right)$ versus time in **toluene** at 313 K for 5-isobutyl-3-(o-tolyl)-2-thiohydantoin(**3**).




Fig. S15 HPLC chromatograms of 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) (ChiralPak IA as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RP**, (c-d) conversion of **RP** to **SP** with time in **ethanol** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S16 HPLC chromatograms of 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) (ChiralPak IA as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **SP**, (c-d) conversion of **SP** to **RP** with time in **ethanol** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S17 HPLC chromatograms of 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) (ChiralPak IA as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **RM**, (c-d) conversion of **RM** to **SM** with time in **ethanol** at 313 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S19 HPLC chromatograms of 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) (ChiralPak IA as the stationary phase, 95:5 Hex:EtOH as the eluent, flow rate : 0.8 ml/min, column temperature: 7°C) (a) the recrystallized product which shows the presence of four isomers, (b) the micropreparatively resolved **SP**, (c-d) conversion of **SP** to **SM** with time in **toluene** at 383 K. (*) The assignments have been done with comparison by the ¹H-NMR spectrum.




Fig. S20 The plot of $\ln\left(\frac{[\text{SP}]_0 - [\text{SP}]_{\text{eq}}}{[\text{SP}] - [\text{SP}]_{\text{eq}}}\right)$ versus time in **toluene** at 383 K for 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) .




Fig. S21 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (**1**) C-5 hydrogen signal change with time in CD₃OD.




Fig. S22 ^1H NMR spectrum of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (**1**) in CDCl_3




Fig. S23 ^{13}C NMR spectrum of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (**1**) in CDCl_3




Fig. S24 ¹H NMR spectrum of 5-benzyl-3-(o-bromophenyl)-2-thiohydantoin (**2**) in CDCl₃




Fig. S25 ^{13}C NMR spectrum of 5-benzyl-3-(o-bromophenyl)-2-thiohydantoin (**2**) in CDCl_3




Fig. S26 ¹H NMR spectrum of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) in CDCl₃.




Fig. S27 ¹³C NMR spectrum of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) in CDCl₃.




Fig. S28 ^1H NMR spectrum of 5-isobutyl-3-(*o*-bromophenyl)-2-thiohydantoin (**4**) in CDCl_3 .




Fig. S29 ^{13}C NMR spectrum of 5-isobutyl-3-(o-bromophenyl)-2-thiohydantoin (**4**) in CDCl_3 .




Fig. S30 ¹H NMR spectrum of 5-benzyl-3-(*o*-tolyl)-2-thiohydantoin (**1**) (crude) in methanol-d₄.




Fig. S31 ^1H NMR spectrum of 5-benzyl-3-(o-bromophenyl)-2-thiohydantoin (**2**) (crude) in methanol- d_4 .




Fig. S32 ¹H NMR spectrum of 5-isobutyl-3-(*o*-tolyl)-2-thiohydantoin (**3**) (crude) in methanol-d₄.




Fig. S33 ^1H NMR spectrum of 5-isobutyl-3-(o-bromophenyl)-2-thiohydantoin (**4**) (crude) in methanol- d_4 .